FDA
approval
· 2024-02-28
FDA Approved: PANCREAZE — Supplemental Application (VIVUS LLC)
Summary
FDA approved a supplemental application for PANCREAZE, a pancreatic enzyme replacement product, submitted by VIVUS LLC.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for PANCREAZE (PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE)